Drugs used to treat rare conditions are earning pharmaceutical companies almost as much as those marketed to the general public, according to a researcher at West Virginia University. Sean Tu, a College of Law professor found ...
Jun 12, 2023
0
71
Incentives intended to stimulate the development of more treatments for rare diseases are being exploited to boost the profits of pharmaceutical companies, new research led by Bangor University shows.
Oct 21, 2016
3
94
Only about one in every 170 children take them. But 'orphan drugs' accounted for 1 in every 15 private insurance dollars spent on children's health care in the United States in 2018, according to a new study. That's up 65% ...
Oct 6, 2020
0
9
A tissue bioengineering product based on patient cells that have been corrected using genomic editing has been designated as an orphan drug by the European Medicines Agency (EMA) for the treatment of Recessive Dystrophic ...
May 7, 2020
0
0
The number of treatments for rare diseases affecting children has increased, a new study suggests. But federal incentives intended to encourage drug development for rare conditions are being used more often to expand the ...
Mar 3, 2020
0
0
The Food and Drug Administration has failed to ensure that drugs given prized rare-disease status meet the intent of a 35-year-old law, federal officials revealed in a report Friday.
Dec 1, 2018
0
1
"It was the best of times, it was the worst of times" is a familiar quote from the opening of Charles Dickens' "A Tale of Two Cities," but the phrase is also applicable to the specialty drug market in the United States today.
Jul 6, 2017
0
0
The U.S. Food and Drug Administration (FDA) reviews and approves new medicines in a shorter timeframe than its peer agency in Europe, the European Medicines Agency (EMA), says a Yale researcher. This finding, which comes ...
Apr 5, 2017
0
0
Prescription drugs are already unaffordable for many: The price tag last year in the United States was $425 billion, one out of every 10 health care dollars spent, and rising.
Apr 4, 2017
0
2
A new analysis by health policy researchers at the University of Massachusetts Amherst who studied the effectiveness of the 1983 Orphan Drug Act (ODA) finds that current incentives "are not sufficiently stimulating orphan ...
Feb 15, 2017
0
0
